LPA and coronary artery disorder: Consistently, ACCELERATE trial demonstrated that in CAD patients with higher hsCRP levels (hsCRP > 2 mg/L) and Lp(a) > 30 mg/dL had an increased risk of recurrent events compared to those with hsCRP < 2 mg/L and Lp(a) > 30 mg/dL [29].